Britt Clynick et al.
The Journal of molecular diagnostics : JMD, 17(6), 644-651 (2015-09-01)
In recent years, there has been increasing use of BRAF-inhibiting drugs for the treatment of various malignancies, including melanoma. However, these agents are associated with the development of other nonmelanoma skin lesions, in particular squamoproliferative lesions such as keratoacanthomas (KAs)